News Hub | News Direct

Transportation

Airlines Automotive Electric Vehicles Logistics Maritime
Article thumbnail News Release

Luftgekühlt 10 celebrates Porsche Turbo Anniversary at Universal Studios Backlot

Luftgekuhlt

As the original Porsche icon, the 911 Turbo has become shorthand for high-performance and cutting edge technology. The cars have graced the bedroom wall of thousands of children around the world who grew up idolizing the signature flared fenders and Whale Tail spoiler. Fifty years later, the 930 model, introduced at the Paris Motor Show on October 3, 1974, not only established the 911 Turbo as a legendary vehicle but inserted its name into the vernacular. In recognition of the importance of the 911 Turbo and to celebrate its birthday, Luftgekühlt 10 will showcase a number of landmark vehicles, including a collection of original and modified examples in true Luft style within the Universal Studios Backlot. And in keeping with Luft tradition, the organizers have secured a number of significant racing examples, such as the 930-based Vasek Polak Racing Porsche 934, which claimed the 1976 Trans-Am Championship. Chassis #0179 will be on display; one of two cars entered that year by the California Porsche dealer. It was driven by George Follmer and Hurley Haywood. Throughout the season, Follmer predominantly raced #0174 until a heavy crash saw him swap to #0179. The 934 dominated the Championship, allowing Follmer to win the title with Haywood in second. The team switched to a 935 for the 1977 season. Luft 10 attendees will be able to enjoy the 911 Turbo exhibits as well as a plethora of significant air-cooled Porsches. We’ll reveal more featured cars in the weeks to come. SUPPORTING EVENTS A full itinerary was recently shared via the Luft newsletter, allowing fans to get their Luft fix in more ways than one. The fun starts on Thursday October 3 with the Luft pre-party at Gunther Werks in Huntington Beach, CA. It runs from 7-11pm and all are welcome. Don’t party all night because you won’t want to miss the Rise & Shine pre-party at Race Service on Venice Blvd in Los Angeles. It takes place on October 4 from 9am-12pm and there will be plenty of coffee available. You can then grab lunch before heading over to the Petersen Automotive Museum on Wilshire Blvd in Los Angeles to celebrate 50 years of the 911 Turbo with fellow enthusiasts. Cocktails and gourmet bites will be served but you’ll need tickets to attend, which are available from the Petersen HERE. The event takes place on Friday October 4 from 6-10pm. Following Luft 10 itself – which takes place on Saturday October 5 at the Universal Studios Backlot in Universal City – enthusiasts can join the Mobil 1 Air-Cooled Caravan on October 6. The rally is celebrating its fourth year with a quintessential Los Angeles rally drive. Registered participants will meet at Hansen Dam Recreation Center at 7am and will end at Porsche Santa Clarita with a Cars & Coffee-style event. Registration info will follow shortly. Porsche Santa Clarita is also hosting Porsche owners and enthusiasts at its Official After Luft Brunch on October 6 from 9am-12pm. Anybody wishing to join the event should please register at DOsorio@galpin.com. LUFT 10 TICKETS Although it’s only been a matter of weeks since tickets went on sale, the Early Access option has already sold out. Vehicle registration also closed once the show car capacity was reached. Fortunately, General Admission tickets are still available (at the time of writing) from luftgekuhlt.com/pages/luft-10. However, we’re duty-bound to remind enthusiasts that the last time we visited the Universal Studios Backlot for Luft 6, tickets sold out quickly and many people were disappointed. Don’t be that person who has to experience the event vicariously through other people’s Instagram accounts! SPONSORS Porsche Classic returns, staged in the iconic Gas Station at Universal Studios – the same location it occupied at Luft 6. The Porsche Classic team will globally launch ORIGINALE 10 to celebrate the tenth anniversary of Luft, along with a photo booth to commemorate your visit. Stop by to receive an exclusive wax-sealed event copy of ORIGINALE. Meguiar’s will be located next door in the Engine Company No. 2 Firehouse. The company will have its latest car care products on display, as well as some emergency supplies for owners of exhibition vehicles who forgot to bring detailer! Meguiar’s specialists will be on-hand to answer questions about the correct products to maintain, protect and restore every finish and material on your car to Reflect Your Passion. There will also be a curated display of modified 911 models for visitors to enjoy. Luftgekühlt is also excited to welcome Kinecta Credit Union to its anniversary event, marking the brand’s first appearance. A Southern California original, Kinecta has branches across Los Angeles, Orange, Ventura and Santa Barbara counties. The company is set to make a memorable debut by showcasing two legendary purple Porsches that are sure to captivate Luft fans. The Kinecta team will be located on New York Street, offering exclusive promotions and exciting merchandise. Keep an eye out for the signature Kinecta purple as they immerse themselves in the vibrant Porsche culture that defines Luftgekühlt. Don’t miss out on this exciting addition to the Luft family! EDITOR’S NOTE Images from Luftgekühlt 6 at Universal Studios Backlot are available here: dropbox.com/scl/fo/0febarq3oac99k05cau6i/AG4Tlv7pzV6i_sjLnv8v86w?rlkey=gn9xw9yjf8gz30jf0nqkm52sf&dl=0 A video is available to download and share here: youtu.be/_OM5NqrC3IQ Porsche 934 photos provided by Linhbergh Nguyen for 000 Magazine. ABOUT LUFTGEKÜHLT In the Porsche vernacular, Luftgekühlt represents all the air-cooled cars in the manufacturer’s history, from the Pre-A 356 through the 993 model line, which ended in 1998. A true Porsche happening, Luftgekühlt is an experiential car culture event centered around a tightly curated list of historically significant or interesting cars, both street and race. There is no set formula for our events, but we're excited by cool venues, fun people, and creative expression, so you can bet those elements will always be included. The team strives to develop wild ideas that celebrate the passion we have for all things air-cooled, including exciting collaborations with likeminded people and brands. For more information, visit luftgekuhlt.com Contact Details Media Contact media@luftgekuhlt.com Company Website https://luftgekuhlt.com/

September 19, 2024 06:28 AM Pacific Daylight Time

Image
Article thumbnail News Release

New Horizon Aircraft (NASDAQ: HOVR) Poised For Growth With Hybrid Aircraft Technology Amid Small-Cap Strength

Benzinga

By Gerelyn Terzo, Benzinga The future has arrived, thanks to electric Vertical Take-Off and Landing (eVTOL) aircraft. eVTOLs are aircraft that launch vertically, similar to a helicopter, rather than a conventional takeoff. Hybrid-electric eVTOL designs have the potential to enable greater speed, range and cargo capacity than fully electric versions and could play an important role in the future of aviation. While eVTOL is still in its early days, with the industry currently in the testing phase, its value is predicted to surpass $30 billion by the next decade amid a CAGR of 15.3% since last year. And while Tesla (NASDAQ: TSLA) is playing a key role with electric vehicles, New Horizon Aircraft (NASDAQ: HOVR) hopes to take on a leadership position in the eVTOL aircraft market segment. Toronto-based New Horizon says it has been an early mover in eVTOL technology with its Cavorite X7 prototype aircraft, a hybrid model built for real-world use cases. Its aircraft takes off vertically, true to eVTOL form. However, once in flight, it reverts to the configuration of a conventional airplane, owing to the company’s patented HOVR wing system. The Cavorite X7 is built to reach speeds of 250 miles per hour, with a fuel capacity of more than 500 miles, making it appropriate for real-world applications like travel when the time comes. Learn more about New Horizon Aircraft’s technology here. New Horizon Puts Pedal To The Metal On eVTOL Aircraft Led by a team of operators, aviators and aerospace engineers, New Horizon has been going full throttle of late as it prepares to fully transition its large-scale prototype aircraft by the end of this year. Chief among New Horizon’s priorities is advancing the development of its hybrid-powered eVTOL aircraft. The company has been making strides from a technical standpoint while also building out its team internally. Flight test program: Among the technical highlights, New Horizon has published results on its flight test program, which it says are surpassing its expectations. The company has performed hundreds of flight tests and is nearing full transition speed, which it anticipates achieving by year-end. Full-scale aircraft development: New Horizon says it is innovating the proprietary patent technologies that are critical to its unique aircraft, including full-scale propulsion units that are essential to its HOVR wing technology. Cooling system and power tests for its full-scale propulsion units continue to unfold and it says the outcomes are positive so far. Encouraging test results extend to the company’s Cavorite X7’s patented HOVR wing design, which the company says enables safer, more durable performance even in the most forbidding conditions. Digital twin development: New Horizon harnesses a hardware-in-the-loop (HITL) digital twin technology to test its aircraft, supporting the rapid testing of large-scale prototype aircraft like the Cavorite X7. Its hybrid technology is fueled by its HOVR wing technology, allowing the aircraft to fly nearly all of its missions in a formation that closely resembles that of a conventional aircraft. Meanwhile, the company says the hybrid power system delivers greater range, speed and payloads in its class. When the Cavorite X7 reaches commercialization, New Horizon expects it to have the power to disrupt the travel industry with its speed, efficiency and cost savings over traditional aircraft. However, its potential use cases also extend to medical evacuation, critical supply delivery, disaster relief and special military missions. “Our unique, customer-first approach prioritizes building a tough eVTOL aircraft that can operate in bad weather, icing conditions and other challenging operational environments. This strategy is gaining strong traction with operators, driving substantial demand,” said Horizon Aircraft CEO Brandon Robinson. To keep pace with this ongoing innovation, New Horizon recently expanded its team with the addition of seasoned engineer Tom Brassington as Chief Technology Officer. New Horizon Says It Could Be Poised To Benefit From Possible Small-Cap Stock Demand Earlier this year, New Horizon made its debut in the publicly traded markets amid a business combination with special purpose acquisition company (SPAC) Pono Capital Three. Most recently, New Horizon returned to the equity capital markets with a $2.9 million public offering. The deal, the closing for which was announced in August, comprised 2.8 million Class A ordinary shares with various types of warrants. New Horizon’s timing is no coincidence, as the company says it could be poised to benefit from an expected ongoing rotation in the equity markets into small cap stocks. While small cap stocks have been gaining attention of late, New Horizon took matters into its own hands. It commissioned its own global poll of investment managers to uncover evidence of investor demand for small- and micro-cap names working with more sustainable technologies, where the upside potential is considered greater than larger companies because they are coming from a lower base. The aerospace company says it found that investor demand is in fact there, with more than three-quarters of survey participants demonstrating an expectation for exposure to these asset classes among institutional investors to increase in the next six to twelve months. Slightly more than one-third (34%) of them say allocations to these stocks could increase by at least 25%. Investors who are interested in participating in New Horizon’s growth story can learn more about this company’s financials here. Read more about New Horizon Aircraft: Pilotless Planes Are Coming, But Not Just Yet, Says New Horizon Aircraft CEO On The Horizon: How One Company Plans To Use Its Innovative Aircraft Design To Revolutionize Regional Air Travel From Stage To Stage: How New Horizon Aircraft's eVTOLs Could Simplify Tour Logistics For Taylor Swift Sustainably Featured photo by ELG21 on Pixabay Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

Flash Transforms Parking at Denver International Airport

Flash

Flash, the leading end-to-end parking technology platform, announced today it has completed an overhaul of public and employee parking at Denver International Airport (DEN) through a contract the City and County of Denver awarded in August 2024. In just 22 days, Flash deployed its platform across the airport’s nine public and employee parking garages and lots, bringing a state-of-the-art parking experience to DEN’s 40,000 employees and the 77.8 million passengers they serve annually. "Flash’s commitment to DEN has been tremendous and we look forward to a bright future that provides innovative solutions to improve the customer experience," said Mark Nagel, Senior Vice President of Parking and Commercial Transportation, Denver International Airport. In its first few weeks of deployment, DEN reports improved traffic flow and reduced wait times for vehicles entering and exiting the airport’s parking facilities. DEN’s deployment of Flash’s platform spans 144 lanes and features 137 kiosks, 97 license plate recognition (LPR) lanes, and 49 automatic vehicle identification (AVI) lanes. With the new AVI lanes, employees can enter and exit automatically in seconds via vehicle-mounted passes that require no interaction with their phones or kiosks. “DEN is the sixth busiest airport in the world and sees millions of parking transactions each year, requiring the highest service level,” said Flash CEO Dan Sharplin. “Our technology breadth and industry-leading scale, plus our maniacal focus on the driver experience, made us confident we could support DEN’s traffic volumes and service levels while getting passengers and employees through parking transactions quickly, and it’s hugely gratifying to see it live.” DEN also benefits from the Flash platform’s design as an enhanced cloud-based parking solution. In the event of an internet, payment processor, network or cloud disruption, the platform maintains continuous operations and critical payment processing capabilities so the airport’s parking facilities stay up and running. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived.. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 12, 2024 09:00 AM Central Daylight Time

Article thumbnail News Release

CollisionRight Reaches 100 Collision Repair Shops

CollisionRight

CollisionRight LLC, a leading regional multi-shop collision repair operator, today announced the acquisition of its 100th shop. The milestone was reached within four years of the company’s founding, culminating in the rapid implementation of its initial market-entry campaign and setting the stage for an equally aggressive growth strategy that aims to increase CollisionRight’s footprint threefold over a five-year span. CollisionRight has reached its 100th-location milestone through the three-shop acquisition of Tripp’s Collision in Michigan. As with each of CollisionRight’s 41 acquisitions to date, Tripp’s will continue to do business under its market-leading local brand while benefiting from the support and efficiency of a unified, large-scale organization. All of CollisionRight’s locations are corporate-owned and run under a common operating system of management, technology, back-office support, and partnerships with insurance carriers and vendors. “Acquiring our 100th store in just a few years is a testament to the hard work and dedication of our remarkable team. It underscores the value that embracing the history of established and trusted collision repair brands can bring,” said Rich Harrison, CEO of CollisionRight. “Driven by our mission to provide exceptional customer service and create the best possible place to work, our team will continue to pursue rapid growth into the coming years.” Having reached the 100-shop milestone, CollisionRight intends to both increase its presence within the 10 states it currently serves and expand its footprint into numerous additional markets. Through strategic acquisitions of local market leaders like Tripp’s—as well as organic growth via insurance-carrier relationships, supply chain optimization, and calibration services—CollisionRight expects to triple its revenue within the next five years. About CollisionRight Headquartered in Columbus, Ohio, CollisionRight provides state-of-the-art collision repair services at 100 corporate-owned locations across 10 states: Illinois, Indiana, Kentucky, Maryland, Michigan, Ohio, Pennsylvania, Tennessee, West Virginia, and Wisconsin. Their team of more than 1,500 collision repair professionals puts more than 90,000 vehicles back on the road each year with a single priority in mind: Getting you back to GO. Every location operates under an established brand that has earned the trust of its local community through decades of prioritizing complete customer satisfaction and convenience. For more information about CollisionRight, or to contact your neighborhood collision repair shop, please visit www.CollisionRight.com. Note to the editor: the company logo, a high-resolution headshot of Rich Harrison, and a copy of the map illustrating CollisionRight’s geographical presence can be found at this link. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website http://www.collisionright.com/

September 11, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Flash Secures $85 Million to Back Special Purpose Vehicle to Propel Growth and Provide Flexible Payment Options

Flash

Flash, the industry-leading end-to-end parking technology platform, today announced that it has closed on $85 million in debt financing for a newly formed special purpose vehicle (“SPV”) to accelerate platform adoption and offer Flash clients an expanded range of flexible payment options. The debt capital, which can be increased up to $100 million, was provided by Vantage Infrastructure (“Vantage”), a leading independent specialist infrastructure credit fund. “Asset owners and operators have a myriad of budgetary and deployment preferences – the payment options we can now extend through the SPV will allow customers to join the Flash platform on terms that work best for them," said Chris Donus, President of Flash. “Innovation in payment options is as critical as platform innovation in pursuit of our vision for the parking industry’s transformation in light of the scale and momentum we're on pace to achieve." Flash’s payment options allow clients to select amongst flexible monthly payment plans that suit their budgets, regardless of scale, asset type, or configuration. This includes EV charging infrastructure and other advanced parking technologies offered by Flash. Flash anticipates extending the SPV structure and partnership with Vantage in future financings. ”We’re pleased to support Flash with a tailored financing solution that enables their team to continue to meet and exceed their clients’ need for better transport related infrastructure,” said Nick Cleary, Senior Partner at Vantage. “This is a great example of the opportunity to upgrade and transform proven traditional infrastructure that saves time and costs for drivers and help build out the EV charging network.” Evercore acted as Flash’s exclusive financial advisor, and Cadwalader, Wickersham & Taft LLP provided legal counsel to Flash. Steptoe LLP acted as counsel to Vantage. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. About Vantage Infrastructure Vantage Infrastructure is an independent infrastructure specialist manager committed to delivering sustainable investment solutions with an equity and debt infrastructure investment portfolio of over US $4 billion invested in infrastructure assets across Europe, North America, and Australia on behalf of global clients. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 09, 2024 09:00 AM Central Daylight Time

Article thumbnail News Release

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

Article thumbnail News Release

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

Article thumbnail News Release

Navigate your Investment Roadmap with Select Sector SPDR ETFs

Select Sector SPDR

In an era where market dynamics shift as swiftly as the winds, Select Sector SPDR ETFs remain a beacon for investors aiming to harness the potential of sector-specific investments. Tailored to meet the diverse needs of both individual and institutional investors, these ETFs chart a course for strategic portfolio management by distilling the vast S&P 500 into accessible segments. Focused Investment Across Diverse Sectors Select Sector SPDR ETFs stand out by offering a focused approach to investing, breaking down the broad landscape of the S&P 500 into key sectors. This segmentation allows investors to pinpoint their investments according to specific economic areas, aligning their portfolios with their investment goals, risk assessments, and market perspectives. Below is a glimpse into the diverse holdings that form the core of the Select Sector SPDR ETFs: Communication Services Select Sector SPDR Fund (XLC): Zooms in on the telecommunications and media sectors, capturing the pulse of digital communication. Consumer Discretionary Select Sector SPDR Fund (XLY): Targets the vibrant consumer goods and services sector, from retail giants to entertainment behemoths. Consumer Staples Select Sector SPDR Fund (XLP): Focuses on essential consumer goods and services, providing stability in fluctuating markets. Energy Select Sector SPDR Fund (XLE): Powers through with a dedicated look at the energy sector, from fossil fuels to renewable resources. Financials Select Sector SPDR Fund (XLF): Encompasses the robust banking, investment, and insurance industries, the backbone of economic infrastructure. Health Care Select Sector SPDR Fund (XLV): Centers on the pharmaceuticals, healthcare equipment, and services sectors, addressing global health needs. Industrials Select Sector SPDR Fund (XLI): Broadens the horizon with manufacturing, construction, and logistics firms. Materials Select Sector SPDR Fund (XLB): Covers the foundational chemicals, construction materials, and packaging industries. Real Estate Select Sector SPDR Fund (XLRE): Opens doors to commercial real estate services and REITs. Technology Select Sector SPDR Fund (XLK): Accelerates into the information technology and electronics sectors, powering innovation and connectivity. Utilities Select Sector SPDR Fund (XLU): Illuminates the path with utility companies, ensuring the flow of essential services. A Path for Strategic Investment By offering a lens through which to invest in specific sectors, Select Sector SPDR ETFs enable investors to steer their portfolios with confidence and clarity. The ETFs’ commitment to transparency and strategic focus empowers investors to adapt and thrive amidst the ebb and flow of market conditions. In the evolving landscape of the financial markets, Select Sector SPDR ETFs stand as a testament to the power of targeted investment. Through detailed sector analysis and dedicated portfolio exposure, these ETFs offer a distinguished pathway for those seeking to refine their investment strategies with sector-specific allocations. About Select Sector SPDR ETFs Select Sector SPDR ETFs are a series of exchange-traded funds designed to provide investors with an effective way to engage in sector-specific investment strategies. By segmenting the S&P 500 into distinct sectors, Select Sector SPDR ETFs furnish investors with the tools necessary for targeted and strategic investment decisions. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007734 EXP 10/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

August 22, 2024 05:00 AM Eastern Daylight Time

12345 ... 98